Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

Objective: To examine changes in levels of plasma amyloid-β (Aβ) peptides, Aβ42 and Aβ40, in relation to onset of Alzheimer disease (AD) in adults with Down syndrome (DS). Methods: Plasma Aβ42 and Aβ40 were measured at initial examination and at follow-up in a community-based cohort of 225 adults with DS who did not have dementia at baseline and were assessed for cognitive/functional abilities and health status and followed at 14- to 20-month intervals. We used Cox proportional hazards modeling to estimate the cumulative incidence of AD by Aβ peptide change group (increasing, no change, or decreasing), adjusting for covariates. Results: Sixty-one (27.1%) of the participants developed AD. At follow-up, a decrease in Aβ42 levels, a decrease in the Aβ42/Aβ40 ratio, and an increase in Aβ40 levels were related to conversion to AD. Compared with the group with increasing levels of Aβ42, the likelihood of developing AD was 5 times higher for those whose plasma Aβ42 levels decreased over follow-up (hazard ratio [HR] = 4.9, 95% confidence interval [CI] 2.1–11.4). Decreasing Aβ42/Aβ40 was also strongly related to AD risk (HR = 4.9, 95% CI 1.8–13.2), while decreasing Aβ40 was associated with lower risk (HR = 0.4, 95% CI 0.2–0.9). Conclusions: Among adults with DS, decreasing levels of plasma Aβ42, a decline in the Aβ42/Aβ40 ratio, or increasing levels of Aβ40 may be sensitive indicators of conversion to AD, possibly reflecting compartmentalization of Aβ peptides in the brain.

[1]  F. Grodstein,et al.  Ten-year change in plasma amyloid beta levels and late-life cognitive decline. , 2009, Archives of neurology.

[2]  S. Hirai,et al.  α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .

[3]  P. Mehta,et al.  Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.

[4]  S. Younkin,et al.  Plasma amyloid β protein is elevated in late-onset Alzheimer disease families , 2008, Neurology.

[5]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[6]  K. Blennow,et al.  CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.

[7]  L. Buée,et al.  Association of plasma amyloid β with risk of dementia , 2009, Neurology.

[8]  D. Geschwind,et al.  Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.

[9]  N. Inestrosa,et al.  Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood , 1995 .

[10]  D. Selkoe,et al.  Normal and abnormal biology of the beta-amyloid precursor protein. , 1994, Annual review of neuroscience.

[11]  B. Tycko,et al.  Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome , 2001, Neuroscience Letters.

[12]  J. Sidtis,et al.  Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  M. Inglese,et al.  Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment , 2004, Neurology.

[14]  E. Matsubara,et al.  Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome , 1999, Annals of neurology.

[15]  R. Petersen,et al.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.

[16]  T. Tokuda,et al.  Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. , 1997, Annals of neurology.

[17]  S A Small,et al.  Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.

[18]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[19]  B. Hyman,et al.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.

[20]  Anders Wallin,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[21]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[22]  I. Kloszewska,et al.  Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.

[23]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[24]  E. Aylward,et al.  Diagnosis of dementia in individuals with intellectual disability. , 1997, Journal of intellectual disability research : JIDR.

[25]  P. Deyn,et al.  No correlation between time-linked plasma and CSF Aβ levels , 2009, Neurochemistry International.

[26]  T. Tokuda,et al.  Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome , 1997 .

[27]  P. Mehta,et al.  Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. , 2001, Neuroscience letters.

[28]  G. Heinrich Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. , 1989, The New England journal of medicine.

[29]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.

[30]  H. Wiśniewski,et al.  Increased plasma amyloid β protein 1–42 levels in Down syndrome , 1998, Neuroscience Letters.

[31]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[32]  J. Growdon,et al.  Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .

[33]  J. Growdon,et al.  Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.

[34]  S. Hirai,et al.  Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. , 1990, Annals of neurology.

[35]  K. Blennow,et al.  Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.

[36]  S. Younkin,et al.  Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. , 2008, Neurology.

[37]  N. Schupf,et al.  Prevalence of dementia in adults with and without Down syndrome. , 1996, American journal of mental retardation : AJMR.

[38]  B. Hyman,et al.  Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men , 2008 .

[39]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[40]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[41]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[42]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[43]  R. Mayeux,et al.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. , 2007, Archives of neurology.

[44]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[45]  N. Schupf,et al.  Dementia in adults with mental retardation: assessment at a single point in time. , 2004, American journal of mental retardation : AJMR.

[46]  J. Growdon,et al.  Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. , 2008, Archives of neurology.

[47]  N. Inestrosa,et al.  Platelets are the primary source of amyloid beta-peptide in human blood. , 1995, Biochemical and biophysical research communications.

[48]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[49]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[50]  H. Wiśniewski,et al.  Increased plasma amyloid beta protein 1-42 levels in Down syndrome. , 1998, Neuroscience letters.

[51]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.